Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
Cipla Health welcomes FSSAI’s new labelling rules for ‘ORS’, reinforces Prolyte ORS as the #AsliORS
MUMBAI, India, Oct. 24, 2025 /PRNewswire/ -- ProlyteORS, the flagship brand of…
Cementos Pacasmayo S.A.A. Announces Annual Dividend
LIMA, Peru--(BUSINESS WIRE)--Cementos Pacasmayo S.A.A. (NYSE: CPAC; BVL: CPACASC1) (“the Company” or…
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences,…
izmo Ltd. Receives Prestigious DSIR Recognition for In-House R&D Unit
BANGALORE, India, Oct. 16, 2025 /PRNewswire/ -- izmo Ltd., has been formally…
LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
Following the Appointment of Dr. Doug Buerger as COO, Jiuzi Holdings, Inc.’s Board Endorses Crypto Asset Investment Policy Allowing Up to $1 Billion Deployment
HANGZHOU, China, Sept. 24, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN;…
NEXEN TIRE Secures SBTi Approval for Greenhouse Gas Reduction Targets
Committed to reducing direct and indirect greenhouse gas emissions through systematic and…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
Event and sports programme decisions made for LA28 and Brisbane 2032
19 September 2025 - The International Olympic Committee (IOC) Executive Board (EB) has approved…